These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6437785)

  • 1. [Treatment of von Willebrand-Jürgens syndrome with "hepatitis-free" factor VIII concentrates].
    Köhler M; Hellstern P; Reiter B; Miyashita C; von Blohn G; Wenzel E
    Dtsch Med Wochenschr; 1984 Nov; 109(47):1800-5. PubMed ID: 6437785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.
    Foster PA
    Thromb Haemost; 1995 Nov; 74(5):1370-8. PubMed ID: 8607125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic studies in von Willebrand's disease: alteration of factor VIII/von Willebrand protein after transfusion with plasma concentrates in patients with von Willebrand's disease.
    Sultan Y; Simeon J; Maisonneuve P; Caen JP
    Thromb Haemost; 1976 Feb; 35(1):110-9. PubMed ID: 1085498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogens and surgery in women with von Willebrand's disease.
    Alperin JB
    Am J Med; 1982 Sep; 73(3):367-71. PubMed ID: 6981997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.
    Hanna WT; Bona RD; Zimmerman CE; Carta CA; Hebert GZ; Rickles FR
    Thromb Haemost; 1994 Feb; 71(2):173-9. PubMed ID: 8191394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of von Willebrand's disease.
    Mannucci PM
    J Intern Med Suppl; 1997; 740():129-32. PubMed ID: 9350194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aortic valve replacement in von Willebrand's disease.
    Young PH; Bouhasin JD; Barner HB
    J Thorac Cardiovasc Surg; 1978 Aug; 76(2):218-22. PubMed ID: 308120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemostasis with cryoprecipitate in patients undergoing surgery for severe von Willebrand disease.
    Mathews V; Srivastava A; Nair SC; Chandy M
    Natl Med J India; 2000; 13(4):188-90. PubMed ID: 11002685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM; Janosević S
    Haematologia (Budap); 1978-1979; 12(1-4):183-8. PubMed ID: 317061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of patients with Type 2B von Willebrand's disease during delivery and puerperium].
    Güth U; Tsakiris DA; Reber A; Holzgreve W; Hösli I
    Z Geburtshilfe Neonatol; 2002; 206(4):151-5. PubMed ID: 12198592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An inherited hemostatic disorder as the cause of menorrhagia].
    Leebeek FW; Lotgering FK
    Ned Tijdschr Geneeskd; 2002 Mar; 146(12):545-8. PubMed ID: 11938574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of the bleeding tendency in uremia with cryoprecipitate.
    Janson PA; Jubelirer SJ; Weinstein MJ; Deykin D
    N Engl J Med; 1980 Dec; 303(23):1318-22. PubMed ID: 6776402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.